BioCentury | Jun 27, 2016
Finance

Nine lives?

Whether Circassia Pharmaceuticals plc's implosion will have a lasting effect on the U.K. biotech sector is going to be hard to tease out now that the Brexit has thrown London and the global markets into...
BC Week In Review | Apr 15, 2013
Clinical News

Norastemizole non-sedating antihistamine data

SEPR announced Phase II results in 381 patients, showing statistically significant improvement at the two higher doses tested. Norastemizole is a metabolite of Johnson & Johnson 's Hismanal astemizole antihistamine. Allergic symptoms such as rhinorrhea,...
BioCentury | Jan 9, 2012
Emerging Company Profile

JDP: Emergency antihistamines

JDP Therapeutics Inc. is hoping its injectable antihistamine can become standard of care for hospitalized patients suffering acute allergic reactions. By avoiding IV diphenhydramine's multiple doses and heavy sedative effects, the company is proposing its...
BC Week In Review | Nov 10, 2008
Clinical News

CRx-197: Phase IIa started

CombinatoRx began a double-blind Phase IIa trial of topical CRx-197 in about 20 patients. CombinatoRx Inc. (NASDAQ:CRXX), Cambridge, Mass.   Product: CRx-197   Business: Autoimmune   Molecular target: NA   Description: Topical cytokine modulator cream...
BC Week In Review | Nov 10, 2008
Company News

CombinatoRx autoimmune, cancer, inflammation news

CombinatoRx restructured and reduced headcount across the company by about 50 (45%) to 90 to conserve cash. The company is seeking partners for its clinical compounds Synavive ( CRx-102 ), CRx-401, CRx-197 and CRx-191. Synavive, a...
BC Week In Review | Jul 28, 2008
Clinical News

CRx-197: Phase IIa start

This half, CombinatoRx will begin a Phase IIa trial. CombinatoRx Inc. (NASDAQ:CRXX), Cambridge, Mass.   Product: CRx-197   Business: Dermatology   Molecular target: NA   Description: Selective cytokine modulator containing loratadine and nortriptyline   Indication:...
BioCentury | Jul 7, 2008
Finance

2Q approvals

2Q approvals Selected second quarter product approvals. The list does not include an FDA approvable letter for Zentase pancrealipase capsules to treat exocrine pancreatic insufficiency from Eurand (NASDAQ:EURX). While not a full approval, the company...
BC Week In Review | Jun 30, 2008
Company News

Merck, Schering-Plough inflammation news

The companies terminated their Schering-Plough/Merck Pharmaceuticals respiratory JV after withdrawing an NDA for a fixed-dose combination tablet of loratadine and montelukast to treat allergic rhinitis symptoms. In April, the companies received a not approvable letter...
BC Week In Review | Jun 30, 2008
Clinical News

Loratadine/montelukast regulatory update

Schering-Plough and Merck withdrew an NDA for a fixed-dose combination tablet of loratadine and montelukast to treat allergic rhinitis. In April, the companies received a not approvable letter from FDA for the product (see BioCentury,...
BC Extra | Jun 28, 2008
Company News

Schering-Plough, Merck withdraw NDA, end JV

Schering -Plough (NYSE:SGP) and Merck (NYSE:MRK) withdrew an NDA for a fixed-dose combination tablet of loratadine and montelukast to treat allergic rhinitis. In April, the companies received a not approvable letter from FDA for the...
Items per page:
1 - 10 of 90